A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis.

[1]  M. Isobe,et al.  Cardiac sarcoidosis: Diagnostic, prognostic, and therapeutic considerations , 1996, Cardiovascular Drugs and Therapy.

[2]  M. Isobe,et al.  Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. , 2001, The American journal of cardiology.

[3]  ICHAEL,et al.  UNDERLYING CAUSES AND LONG-TERM SURVIVAL IN PATIENTS WITH INITIALLY UNEXPLAINED CARDIOMYOPATHY , 2000 .

[4]  G. Hunninghake,et al.  ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[5]  T. Michele,et al.  The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. , 1999, Medicine.

[6]  G. Hunninghake,et al.  ATS/ERS/WASOG statement on sarcoidosis , 1999 .

[7]  G. Berry,et al.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. , 1997, The New England journal of medicine.

[8]  S. Goto,et al.  Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. , 1997, Journal of molecular and cellular cardiology.

[9]  R. Virmani,et al.  Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[10]  G. Trinchieri,et al.  Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. , 1996, Journal of immunology.

[11]  L. Cooper,et al.  Data on giant cell myocarditis sought for new study. , 1996, Circulation.

[12]  L. Cooper,et al.  Giant cell myocarditis study group. , 1995, Journal of the American College of Cardiology.

[13]  L. Cooper,et al.  Announcement of multicenter giant-cell myocarditis study. , 1995, The American journal of cardiology.

[14]  G. Gregoratos,et al.  Guidelines for training in adult cardiovascular medicine. , 1995, Journal of the American College of Cardiology.

[15]  L. Cooper,et al.  Giant Cell Myocarditis Study Group. , 1995, American heart journal.

[16]  E. Kasper,et al.  Myocardial sarcoidosis: Course and management , 1992 .

[17]  J. Fallon,et al.  Giant Cell Versus Lymphocytic Myocarditis: A Comparison of Their Clinical Features and Long‐term Outcomes , 1991, Circulation.

[18]  H. Fleming,et al.  Chapter 8 – Sarcoid heart disease , 1983 .

[19]  S. Bailey,et al.  Sarcoid Heart Disease , 1981, Journal of the Royal College of Physicians of London.

[20]  M. Davies,et al.  Idiopathic giant cell myocarditis--a distinctive clinico-pathological entity. , 1975, British heart journal.

[21]  W. G. Brown,et al.  ISOLATED MYOCARDITIS. , 1964, Texas state journal of medicine.

[22]  S. Rab,et al.  Giant-cell myocarditis. , 1963, Lancet.

[23]  H. Tesluk.  Giant cell versus granulomatous myocarditis. , 1956, American journal of clinical pathology.

[24]  JohnH. Johnson,et al.  Sarcoidosis of the heart , 1944 .

[25]  O. Saphir,et al.  Acute isolated myocarditis , 1929 .